MKT 9205 - 2223

Longer, fuller lives with digital-first care and research

(HealthTech Firm Medopad Reveals New Name and Logo - Logo-Designer.co, 2020)

(Huma | Longer, fuller lives, n.d.)

 5 continents – UK/England, Asia-Pacific, USA,

Profile Middle East, South Africa (Huma - About us, n.d.).

Huma, previously known as medopad, Over 500 employees (Crunchbase, n.d.).

was set up in 2011 with headquarters
based in London. it creates apps that
use health data from hospital databases
to help medical practitioners monitor
patients (Wong, 2020).
Huma
16 investors (CrunchBase, AstraZeneca and
Future Fifty ) (Crunchbase, n.d.).
Huma combines data from biomarkers
Huma has raised a total of $217M in funding
with predictive algorithms both to help (Crunchbase, n.d.)
monitor patients, and uses the same
technology to help researchers and
Acquisition of 5 organizations. Their most recent
pharmaceutical companies run clinical acquisition was Alcedis on Jan 9, 2023
trials (Lunden, 2021). (Crunchbase, n.d.).
Products
Remote Patient Monitoring: A regulated 'Software as a Medical"
platform, that enables clinicians and HCPs to remotely monitor
patient cohorts across a range of therapeutic areas and care
pathways (CB Insights, n.d.).
Huma builds regulated Software as a Medical Device (SaMD)
solutions and launches, scales, and sustains it across
thousands of hospitals, clinics and patients across the world
(SaMD - Software medical device, n.d.)
DCT and Clinical Trial Management: A decentralized, digital
clinical trial platform, that enables recruitment, on-boarding,
onward engagement and real world data collection for clinical
trials (CB Insights, n.d.).
Virtual wards: Huma’s expertise in building and deploying
virtual wards across multiple therapeutic areas has helped NHS
Trusts around the country double clinical capacity1, reduce
elective backlogs, and improve patient outcomes and
experience. We understand patient and clinician needs, based
on over a decade of experience and learnings from more than
450 deployments (Explore Huma’s award winning digital health
solution for virtual wards, n.d.)
Critical Analysis of Remote Patient Monitoring

This Photo by Unknown Author is licensed under CC BY-SA-NC

This Photo by Unknown Author is licensed under CC BY-SA

The ‘hospital at home’ system comprises a patient app and a clinical portal. It is already used across England, Wales, Germany and the UAE to help people with
CVD, COVID-19, musculoskeletal surgery and more. In diabetes, early work with a healthcare consortium in London, UK has found that patients lost 4.1kg in weight
and had an average reduction in average blood glucose levels (HbA1c) of 17 mmol / mol in HbA1c. The technology has almost doubled clinical capacity through
virtual wards and helped clinicians spot and reprioritize nearly 10% of their cardiac surgery patients on waiting lists who were deteriorating (Huma and Tamer bring
digital “hospital at home” platform to the Kingdom of Saudi Arabia, 2022).

The technology is used to help people with CVD and diabetes in a number of ways. The app can capture patient-generated data through the phone’s camera and
accelerometers, or by connecting to medical devices and providing clinically approved questionnaires. Clinicians are able to monitor groups of patients at once, and
the system flags any potentially deteriorating patients so that the clinician can spot who may need their attention. In addition, the system can point patients to
appropriate educational content and provide reminders about their treatment plan (Huma and Tamer bring digital “hospital at home” platform to the Kingdom of
Saudi Arabia, 2022).
Improving Clinical Outcomes
27m+ Huma’s
digital-first
health
platforms
support a global
network of
patients

3000+ hospitals and

×2 Huma’s platform
clinics supported across
can almost double
clinical capacity and
reduce readmission
HUMA Huma platforms to
secure the most
sustainable impact for
rates by >30%
patients

90-95% adherence
and retention rates
across our care and
research deployments
are the result of high
engagement rates (Hospital at home, n.d.)
Product Impact

HSJ Value Awards 2021

North-West London COVID-19 Primary Care
Remote Monitoring

Due to the significant challenges posed by the

first wave of Covid-19, CCGs in North-West
London (NWL) designed and piloted a ‘virtual-
ward’ to enable better patient care, enhance
clinical capacity and improve access for patients
presenting with moderate Covid symptoms. The Increase
Patient
pilot sought to safely monitor patients in the medications
community by utilizing scaled-up primary care
Provide Real world
hubs, which provided remote monitoring Data and Evidence to
through phone calls and/or a mobile Pharma Companies,
application, provided by Huma. The pilot Medtech companies
started in Hillingdon and Central London CCGs and Health
Organisations
initially (covering ~730k patients), and was
successfully scaled across the NWL Integrated
Care System, covering 2.4 million patients.
Competitive Advantage Huma
Primary Advantage:
• Feature Set (CB Insights, n.d.).
Differentiators:
• Product UX and Scientific Research and Evidence Regulatory approvals
• (Class 1) with Class IIb pending (CB Insights, n.d.).

Medable I
-Decentralized clinical trial software company. The company's Software-as-
a-Service (SaaS) cloud platform aims to provide a path to secure, HIPAA-
compliant healthcare applications for researchers, startups, pharma, payers,
and academia research, healthcare delivery, and personalized and predictive
medicine (CB Insights, n.d.).

Science 37 (NASDAQ: SNCE).

-It enables universal access to patients and providers for clinical trials.
-Its operating system is fused with networks of telemedicine investigators, mobile
nurses, remote coordinators, patient communities, and connected devices (CB
Insights, n.d.).

BrightInsight
• Provides a global platform for biopharma and MedTech regulated digital health solutions.

• The company helps accelerate time to market for apps, algorithms, medical devices, connected
combination products, diagnostics, and Software as a Medical Device (SaMD) (CB Insights, n.d.).
Research Studies

• Huma has been continuing to contribute essential data to ongoing medical

research. One that the company can disclose that is not directly related to Covid-
19 is a heart study for Bayer; and one that is related to Covid-19 — finding better
biomarkers (specifically in looking at digital phenotypes) to detect Covid-19
infections earlier — called the Cambridge Fenland study (Lunden, 2021).
 
• Huma’s work has included partnering with the NHS early on to ship some 1
million oxygen saturation devices to monitor how patients’ levels were faring,
since that was early on discovered to be a leading indicator of whether a patient
would need urgent medical care (Lunden, 2021).
THANK YOU
Onimim Johnarry - 25597545

A m i n a t Olanrewaju - 27215755

Ali Sabir - 27416778

Khaqan jamil -27157378

Maninder kaur - 27154722

Tutor: Dr Jialin (Penny) Hardwick

25597545@students.Lincoln.ac.uk
References
• Proofpoint UK. (2022) What Is HIPAA Compliance? HIPAA Laws and Rules. [online] Available at:
https://www.proofpoint.com/uk/threat-reference/hipaa-compliance [Accessed 13 March 2023].
• Huma. (n.d.) Explore Huma’s award-winning digital health solution for virtual wards. [online]
Available at: https://www.huma.com/virtual-wards [Accessed 13 March 2023].
• Huma. (n.d.) SaMD: Software medical device. [online] Available at:
https://www.huma.com/software-medical-device-samd [Accessed 13 March 2023].
• Huma. (n.d.) Longer, Fuller Lives. [online] Available at: https://www.huma.com/ [Accessed 13
March 2023].
• Huma. (2022) Huma and Tamer bring a digital ‘hospital at home’ platform to the Kingdom of
Saudi Arabia. [online] Available at:
https://www.huma.com/blog-post/huma-and-tamer-bring-digital-hospital-at-home-platform-to-
the-kingdom-of-saudi-arabia
[Accessed 13 March 2023].
• CB Insights. (n.d.) CB Insights. [online] Available at:
https://app.cbinsights.com/profiles/c/YYYRD/analystInsights#products [Accessed 13 March
2023].
References Cont’d
• Lunden, I. (2021) Huma, which uses AI and biomarkers to monitor patients and for medical research, raises $130 million. [online] TechCrunch.
Available at:
https://techcrunch.com/2021/05/11/huma-which-uses-ai-and-biomarkers-to-monitor-patients-and-for-medical-research-raises-130m/
[Accessed 13 March 2023].
• CB Insights. (n.d.) Market Profile: Huma. [online] Available at: https://app.cbinsights.com/market-profile/1339?tab=esp [Accessed 13 March
2023].
• Huma. (n.d.) Longer, Fuller Lives. [online] Available at: https://www.huma.com/ [Accessed 13 March 2023].
• Huma. (n.d.) Life Sciences: Decentralized Clinical Trials. [online] Available from: https://www.huma.com/decentralized-clinical-trials [Accessed
13 Mar. 2023].
• CB Insights. (n.d.) [online] Available from: https://app.cbinsights.com/profiles/e/vDYR/analystBriefing#competition [Accessed 13 Mar. 2023].
• Huma. (n.d.) Life Sciences: Decentralized Clinical Trials. [online] Available from: https://www.huma.com/decentralized-clinical-trials [Accessed
13 Mar. 2023].
• Wong, H. (2020) Medopad rebrands as Huma in a bid to “humanize healthcare.” Design Week. [online] Available from:
https://www.designweek.co.uk/issues/14-19-april-2020/huma-rebrand/ [Accessed 13 Mar. 2023].
• CB Insights. (n.d.) [online] Available from: https://app.cbinsights.com/profiles/c/YYYRD/analystInsights [Accessed 13 Mar. 2023].
• Hospital at home (n.d.) Available from: https://www.huma.com/hospital-at-home.
• Crunchbase (n.d.) Summary available from: https://www.crunchbase.com/organization/medopad [accessed March 11, 2023].
• Crunchbase (n.d.) Huma company financials Available from: https://www.crunchbase.com/organization/medopad/company_financials
[accessed March 11, 2023].
• HealthTech Firm Medopad Reveals New Name and Logo: logo-designer.co (2020) Available from:
https://www.logo-designer.co/digital-health-company-medopad-reveals-new-name-and-logo-design/.